---
document_datetime: 2025-11-05 11:45:38
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/grasustek-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: grasustek-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5376266
conversion_datetime: 2025-12-22 10:50:52.534524
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Grasustek

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 04/11/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000307856                      | Update of the package leaflet with revised contact details of local representatives. Additionally, the MAH took the opportunity to make minor editorial and grammatical changes in the French and Slovak translation.                                                                                                                                                                                                                        |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000272956 | This was an application for a group of variations. B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted B.I.c.2 Change in the specification parameters and/or limits of the immediate packaging of the active substance - B.I.c.2.b Addition of a new specification parameter to the specification with its corresponding test method - Accepted | 17/06/2025 | N/A |
| Variation type IA / EMA/VR/0000244623 | B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted                                                                                                                                                                                                       | 14/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000274399   | - -   |
|------------------------------|-------|